| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 01/12/2006 | WO2004071407A3 Antisense modulation of ptp1b expression |
| 01/12/2006 | WO2004067712A3 Intracellular signaling molecules |
| 01/12/2006 | WO2004058182A3 Use of synergistic bacteriophage lytic enzymes for prevention and treatment of bacterial infections |
| 01/12/2006 | WO2004045497A3 Cd26-based therapies for cancers and immune disease |
| 01/12/2006 | WO2004032851A3 Screening and therapeutic methods relating to neurogenesis |
| 01/12/2006 | WO2003089596A3 Novel prostate tumor-specific promoter |
| 01/12/2006 | WO2003084470A3 Compositions and methods for targeted biological delivery of molecular carriers |
| 01/12/2006 | WO2003076572A3 Novel nucleic acid molecules and polypeptides encoding baboon tafi |
| 01/12/2006 | WO2002020715A3 Peptide conjugated anti-cancer prodrugs |
| 01/12/2006 | US20060009632 Nucleotide sequences coding metalloenzymes and/or aggrecanase for use in identifying modulators for prevention and treatment of bone disorders |
| 01/12/2006 | US20060009622 inflammatory bowel disease, rheumatoid arthritis, acromegaly, tuberculosis, tumor of the lung, breast, brain, eye, prostate or colon, a tumor of neuroendocrine origin, an angiogenesis disease that causes inappropriate proliferation of blood vessels, retinal macular degeneration or diabetic neuropathy |
| 01/12/2006 | US20060009528 Cannabinoid receptor ligands |
| 01/12/2006 | US20060009527 Method of treating TRX mediated diseases |
| 01/12/2006 | US20060009526 Method of treating TRX mediated diseases |
| 01/12/2006 | US20060009516 Use of ingap for reversing diabetes |
| 01/12/2006 | US20060009475 Quinazolinone compounds in combined modalities for improved cancer treatment |
| 01/12/2006 | US20060009429 Antiandrogen oligonucleotides usable for the treatment of dermatological androgen-related disorders relating to androgen metabolism, their pharmaceutical compositions, their uses and treatment method |
| 01/12/2006 | US20060009414 Protecting a muscarinic acetylcholine receptor in patient; prevent tissue damage, increasing the efficacy of a therapeutic agent |
| 01/12/2006 | US20060009413 Methods and compositions for protecting or treating muscarinic receptors through administration of pyrophosphate analog in subjects exposed to toxic or carcinogenic metals or metal ions |
| 01/12/2006 | US20060009412 Methods and compositions useful for modulation of angiogenesis using tyrosine kinase Src |
| 01/12/2006 | US20060009410 Effects of apolipoprotein B inhibition on gene expression profiles in animals |
| 01/12/2006 | US20060009408 siRNA-Mediated gene silencing with viral vectors |
| 01/12/2006 | US20060009407 Administering arginine, lysine; cardiovascular disorder therapy |
| 01/12/2006 | US20060009406 Vectors having both isoforms of beta-hexosaminidase |
| 01/12/2006 | US20060009403 Dna demethylase antisense and chemotherapy combination |
| 01/12/2006 | US20060009398 Compositions comprising gelatin-glycine and carotenoids |
| 01/12/2006 | US20060009397 New use |
| 01/12/2006 | US20060009396 inhibiting platelet aggregation; for treatment of thrombosis, restenosis, hypertension, heart failure, arrhythmia, inflammation, angina, stroke, atherosclerosis, ischemic conditions, angiogenesis, cancer, and neurodegenerative disorders |
| 01/12/2006 | US20060009395 Compounds for control of appetite, blood pressure, cardiovascular response, libido, and circadian rhythm |
| 01/12/2006 | US20060009394 alkylating a 4-protected hydroxyl pyroglutamic acid derivative with an alkylating agent to prepare a 4-protected hydroxyl-4-alkylglutamic acid derivative, followed by the steps of hydrolysis and deprotection |
| 01/12/2006 | US20060009393 Immunogenic epitopes for fibroblast growth factors 5 (FGF-5) |
| 01/12/2006 | US20060009392 Antineoplastic peptides |
| 01/12/2006 | US20060009391 Method and peptide for regulating cellular activity |
| 01/12/2006 | US20060009390 Dose of an angiogenic factor and method of administering to improve myocardial blood flow |
| 01/12/2006 | US20060009389 Synergistic; proliferative agents for bone and nervous tissue; can also include an antiinflammatory agent to treat rheumatoid or osteoarthritis; time-release formulations in dosage forms of solutions, gels, pastes or putties |
| 01/12/2006 | US20060009388 Treatment of conditions involving demyelination |
| 01/12/2006 | US20060009387 Apo-2 ligand/trail formulations |
| 01/12/2006 | US20060009386 Preventing grampositive bacterial infection via upregulation of interleukin expression and down-regulating pro-inflammatory cytokine expression |
| 01/12/2006 | US20060009385 Multiple-variable dose regimen for treating TNFalpha-related disorders |
| 01/12/2006 | US20060009384 Novel use of peptide compounds for treating status epilepticus or related conditions |
| 01/12/2006 | US20060009383 Stable bactericidal/permeability-increasing protein products and pharmaceutical compositions containing the same |
| 01/12/2006 | US20060009382 Use of a CD28 binding pharmaceutical substance for making a pharmaceutical composition with dose-dependent effect |
| 01/12/2006 | US20060009381 Annexins, derivatives thereof, and annexin-cys variants, as well as therapeutic and diagnostic uses thereof |
| 01/12/2006 | US20060009380 Isolated deoxyribonucleic acid fragment that codes for the calcium binding proteins; treating skin disorders, like dry skin, hyperkeratosis, parakeratosis, psoriasis, ichthyosis, and neoplasia; cosmetics |
| 01/12/2006 | US20060009379 Methods for controlling proliferation of cells |
| 01/12/2006 | US20060009378 Novel galectin sequences and compositions and methods utilizing same for treating or diagnosing arthritis and other chronic inflammatory diseases |
| 01/12/2006 | US20060009377 Long lasting synthetic glucagon like peptide (GLP-1) |
| 01/12/2006 | US20060009376 storable medicaments produced from active ingredient which are virus safe; has a therapeutic protein selected from fibrinogen, Factor VIII, Factor V, Factor XIII, clotting Factors II, VII, IX and X of the prothrombin complex, and an atoxic, virus-safe protease inhibitor |
| 01/12/2006 | US20060009375 Site-specific drug delivery |
| 01/12/2006 | US20060009374 Antibacterial peptide |
| 01/12/2006 | US20060009373 Method for treating diabetic wounds |
| 01/12/2006 | US20060008901 Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| 01/12/2006 | US20060008900 Pigment epithelium-derived factor: characterization, genomic organization and sequence of the PEDF gene |
| 01/12/2006 | US20060008892 Methods of and pharmaceutical compositions for improving implantation of embryos |
| 01/12/2006 | US20060008882 Antibody or fragment that specifically binds to CK alpha -5 polypeptides; may be chimeric antibody or fragment thereof, a single chain antibody, a Fab fragment, or a F(ab')2 fragment; Western blot or an enzyme-linked immunosorbent assay; hybridoma that produces the antibody |
| 01/12/2006 | US20060008881 Mammalian diabetes-mediating proteins |
| 01/12/2006 | US20060008873 Cloning and sequencing of allergens of dermatophagoides (house dust mite) |
| 01/12/2006 | US20060008872 substitutes valine for phenylalanine residue in an alpha -helix domain participating in the binding of a human cytokine protein to a corresponding receptor |
| 01/12/2006 | US20060008857 Cap-binding protein |
| 01/12/2006 | US20060008846 Methods are described for the screening and identification of antagonist for TGF- beta superfamily members, in particular activin-A antagonist; antagonism of TGF- beta receptors by variants of the TGF- beta superfamily of ligands |
| 01/12/2006 | US20060008844 Polypeptides comprising monomer domains that bind to c-MET; polynucleotide encoding the polypeptide; cancer; drug screening |
| 01/12/2006 | US20060008829 Multimarker panel based on PIGF for diabetes type 1 and 2 |
| 01/12/2006 | US20060008819 Novel 38594, 57312, 53659, 57250, 63760, 49938, 32146, 57259, 67118, 67067, 62092, FBH58295FL, 57255, and 57255alt molecules and uses therefor |
| 01/12/2006 | US20060008800 Unc-13 in the modulation of neurotransmission and secretion events |
| 01/12/2006 | US20060008797 Peptide that that binds to microglial receptors; may be conjugated to a carrier molecule that increases transport across the blood-brain barrier; treating neurological effects of cerebral ischemia or cerebral inflammation |
| 01/12/2006 | US20060008544 Methods for enhancing antioxidant enzyme activity and reducing C-reactive protein levels |
| 01/12/2006 | US20060008543 Forming antioxidant-promoting composition by mixing bacopa monniera extract having 45& bacosides or greater, silybum marianum extract, Withania somnifera powder, Camellia sinensis powder having 98% polyphenols and 45% epigallocatechin gallate, and turmeric extract having 95% curcumin |
| 01/12/2006 | US20060008532 Complexes of protein crystals and ionic polymers |
| 01/12/2006 | US20060008530 Tissue matrix system |
| 01/12/2006 | US20060008479 Methods and compositions to generate immunity in humans against self tumor antigens by immunization with homologous foreign proteins |
| 01/12/2006 | US20060008478 Immunoadjuvant |
| 01/12/2006 | US20060008476 Adjuvanted antigenic meningococcal compositions |
| 01/12/2006 | US20060008475 Shiga toxin B-subunit as a vector for tumor diagnosis and drug delivery to Gb3 expressing tumors |
| 01/12/2006 | US20060008466 Methods for treating and preventing microbial infections |
| 01/12/2006 | US20060008463 Tumor antigen peptides derived from cyclophilin B |
| 01/12/2006 | US20060008462 Treatment of mammalian reaction of ige interactions |
| 01/12/2006 | US20060008460 Inhibits B-cell activation by binding to protein receptor on helper T-cell membrane; treatment of allergy or autoimmune disease |
| 01/12/2006 | US20060008457 Use of an active substance binding to CD28 for producing a pharmaceutical composition for the treatment of B-CLL |
| 01/12/2006 | US20060008456 Natural humanized antibody |
| 01/12/2006 | US20060008455 Methods and compositions for using aleveolar macrophage phospholipase A2 |
| 01/12/2006 | US20060008454 Use of a compound for enhancing the expression of membrane proteins on the cell surface |
| 01/12/2006 | US20060008448 Inhibition of li expression in mammalian cells |
| 01/12/2006 | US20060008447 Comprises purified mannitol which reduces formation of interferon-beta adducts |
| 01/12/2006 | US20060008446 Delivering antiinflammatory cytokines to nervous system using gene therapy techniques |
| 01/12/2006 | US20060008440 Cosmetic or dermatological preparations having a content of anti-freezing proteins and/or anti-freezing glycoproteins |
| 01/12/2006 | US20060008425 Antiplaque oral composition containing enzymes and cyclodextrins |
| 01/12/2006 | US20060008420 Nasal spray formulation and method |
| 01/12/2006 | US20060006827 Motor control apparatus having current supply phase correction |
| 01/12/2006 | DE102004030504A1 Multi-particulate formulation, useful to generate a pH-value dependent active substance release in treating inflammatory intestinal diseases, comprises encapsulated medicine and/or natural substances |
| 01/12/2006 | CA2572707A1 Annexins, derivatives thereof, and annexin-cys variants, as well as therapeutic and diagnostic uses thereof |
| 01/12/2006 | CA2572643A1 Novel carbamylated epo and method for its production |
| 01/12/2006 | CA2572318A1 Treatment of cancer |
| 01/12/2006 | CA2572129A1 Viral particle-like construct and method of forming the same under physiological conditions |
| 01/12/2006 | CA2572098A1 B7-dc binding antibody |
| 01/12/2006 | CA2571957A1 Methods and compositions using cd3 agonists |
| 01/12/2006 | CA2571752A1 Tie receptor and tie ligand materials and methods for modulating female fertility |
| 01/12/2006 | CA2571683A1 Methods and reagents for the treatment of metabolic disorders |
| 01/12/2006 | CA2571598A1 A method of pre-sensitizing cancer prior to treament with radiation and/or chemotherapy and a novel cytokine mixture |
| 01/12/2006 | CA2571577A1 S1-5 containing protein preparation |
| 01/12/2006 | CA2571463A1 Diaminooxidase-containing pharmaceutical compositions |